Syra Health (SYRA) investor relations material

Executive summary

• Achieved first profitable quarter in Q1 2026 with net income of $240,979, reversing a net loss of $472,265 in Q1 2025.

• Revenue grew 22% year-over-year to $2,273,520, driven by population health services and solutions.

• Gross profit margin improved to 43% from 32% year-over-year.

• Operational efficiency improved with a 27% reduction in salaries and benefits and a 26% decrease in SG&A expenses.

• EPS improved to $0.02 from $(0.04) in Q1 2025.

Financial highlights

• Net revenues: $2,273,520 in Q1 2026 vs. $1,857,774 in Q1 2025.

• Gross profit: $971,255 in Q1 2026, up from $589,156 in Q1 2025.

• Operating income: $190,983 in Q1 2026, compared to a loss of $473,334 in Q1 2025.

• Adjusted EBITDA reached $244,495, up from $(462,239) year-over-year.

• Cash and cash equivalents: $2,922,318 as of March 31, 2026, with no long-term debt.

Outlook and guidance

• Management expects continued pressure on revenue timing and volume due to government budget constraints and delays in contract awards.

• Expects quarterly variability due to milestone-based contracts but remains on track for full-year profitability.

• Additional capital may be required to sustain operations over the next twelve months.

• Management confident in profitability trajectory by year-end, supported by expanding partnerships and demand.